1. Hong Kong Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Lee's Pharmaceutical Holdings Limited

Lee's Pharmaceutical Holdings Limited

LPCUF
Lee's Pharmaceutical Holdings LimitedUS flagOther OTC
0.19
USD
- -
- -
112.06MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.32
1.76
1.6
1.58
1.71
1.92
2.06
2.07
2.15
2.09
1.79
- -
2.44
2.09
Basic EPS, GAAP
0.28
0.36
0.4
0.43
0.39
0.71
0.21
0.22
3.38
0.09
0.03
- -
0.16
0.09
Free Cash Flow per Basic Share
-0.08
0.17
-0.13
0.21
0.17
0.03
0.07
-0.24
-0.27
0.12
-0.08
- -
0.17
- -
Dividend per Share
0.06
0.08
0.1
0.11
0.11
0.1
0.1
0.07
0.06
0.04
0.02
- -
0.05
- -
Book Value per Share
0.05
0.05
0.05
0.05
0.05
0.05
2.53
0.05
0.05
6.07
6.1
- -
6.35
6.07
Tangible Book Value per Share
1.21
1.37
2.02
1.82
2.04
2.56
3.01
2.15
2.49
1.38
1.49
- -
0.94
1.38
Basic Weighted Avg Shares
530
543
576
589
591
592
592
588
589
589
589
- -
589
589
Sales/Revenue/Turnover
697
955
922
930
1,009
1,138
1,219
1,217
1,266
1,233
1,053
1,400
1,436
1,233
Operating Margin (%)
24.76
24.36
26.8
34.13
24.35
17.29
15.34
7.39
-13.69
6.21
-0.7
5.53
5.28
6.21
Depreciation Expense
17
29
45
49
61
68
94
128
147
152
150
148
156
- -
Net Income, GAAP
150
193
229
252
233
418
126
129
1,987
51
17
93
92
51
Effective Tax Rate (%)
15.38
18.13
16.12
17.76
21.23
12.68
48.45
41.41
0.48
32.46
35.2
30.07
30.55
32.46
Profit Margin (%)
21.59
20.19
24.84
27.1
23.06
36.77
10.3
10.63
156.95
4.16
1.59
6.65
6.4
4.16
Working Capital
370
422
560
525
442
328
533
295
41
2
8
13
39
2
LT Debt
- -
- -
1
1
1
1
13
8
92
80
75
70
87
80
Total Equity
852
999
1,517
1,635
1,797
2,238
2,477
2,115
2,391
1,843
1,961
1,549
1,900
1,843
Return on Invested Capital (%)
18.67
18.75
15.24
15.31
10.39
7.92
3.76
2.09
-6.93
2.21
-0.23
2.73
2.62
2.21
Return on Capital (%)
132.04
131.03
170.14
159.43
165.93
290.46
18.74
18.34
1,077.12
3.16
0.56
3.39
3.66
3.16
Return on Common Equity (%)
568.15
712.23
809.71
856.52
787.67
1,414.31
16.44
16.94
6,753.59
2.85
0.47
2.56
2.48
2.85

Capital Structure

FRC

•

in mil. unless spec.
Jun'22
Sep'22
Dec'22
ST Debt
146
- -
84
LT Borrowings
84
- -
77
LT Finance Leases
6
- -
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
589
- -
589
Market Capitalization
242,132,852,916
71,243,486
70,876,166

Working Capital

FRC

•

in mil. unless spec.
Jun'22
Sep'22
Dec'22
Total Current Assets
882
- -
652
Cash, Cash Equivalents & STI
368
- -
189
Accounts Receivable, Net
144
- -
111
Inventories
263
- -
249
Total Current Liabilities
850
- -
650
Payables & Accruals
- -
- -
- -
ST Debt
146
- -
84
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.65%
-0.36%
22.68%
Free Cash Flow
-94.69%
-55%
194.16%
Net Income, GAAP
174.33%
345.62%
-1.25%
Sales/Revenue/Turnover
5.14%
4.47%
2.57%
Total Cash Common Dividend
0.02%
5.68%
56.67%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
1,053
2024
- -
- -
- -
- -
1,400
2025
- -
- -
- -
- -
1,436

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.03
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
0.16

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.02
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
0.05

Company Description

APIChat
CEO
Siu Fong Lee
Full Time Employees
1,022
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Address
Building 20E Sha Tin Hong Kong
IPO Date
Jul 16, 2021
Website
leespharm.com
Similar Companies
InterCure Ltd. (INCR.TA)
DRI Healthcare Trust (DHT-UN.TO)
Laboratorio Reig Jofre, S.A. (RJF.MC)
Intra-Cellular Therapies, Inc. (ITCI)
The Greenrose Holding Company Inc. (GNRS)
Alkem Laboratories Limited (ALKEM.NS)
Business
Lee's Pharmaceutical Holdings Limited (HKEx: 950), founded in 1994 and headquartered in Sha Tin, Hong Kong, operates as an integrated research-driven biopharmaceutical company focused on the development, manufacturing, sales and marketing of proprietary, generic and licensed-in pharmaceutical products primarily in mainland China, Hong Kong, Macau and Taiwan. The company addresses key therapeutic areas including cardiovascular, infectious diseases, women's health, pediatrics, rare diseases, oncology, dermatology, obstetrics, gynecology, urology and ophthalmology; its core offerings encompass self-developed products such as Fondaparinux Sodium Injection (Lichangqing), Nadroparin Calcium Injection (Litengjing), Treprostinil Injection (Ruineier), Socazolimab Injection, Adapalene and Clindamycin Hydrochloride Gel, Azilsartan Tablets and Sodium Phenylbutyrate Granules, alongside licensed-in products including INOmax (Nitric Oxide for Inhalation), Teglutik, Trittico, Natulan (Procarbazine Hydrochloride Capsules) and Adasuve (Loxapine for Inhalation). Manufacturing facilities located in Hefei, Anhui province and Guangzhou support production of injectables, lyophilized powders, gels, solid dosages, ophthalmic products and medical devices, with over 40 products in various development stages derived from internal R&D platforms like snake venom technology, low molecular weight heparin and water-based gel delivery systems, as well as partnerships with around 30 international firms from the United States, Europe and Japan. Recent developments include the launch of a new pre-filled production line with isolator technology at Zhaoke Pharmaceutical (Hefei) in June 2025 to enhance capacity for volume-based procurement products like Fondaparinux Sodium Injection and Nadroparin Calcium Injection; a strategic partnership with Shaohe Biotechnology in August 2025 to develop probiotic solutions for public health; commercial launches of in-house Adapalene and Clindamycin Hydrochloride Gel and in-licensed INOmax and INOmax DSIR Plus in 2024; and ongoing Phase I clinical trials for AU409 initiated in July 2024. The company maintains an investment in Zhaoke Ophthalmology Limited and reported a 5.5% revenue increase to HK$694.8 million in the first half of 2025, driven by expanded production and product portfolio growth.